Articles tagged with Cancer Genetics
Researchers identified three distinct molecular subtypes of follicular lymphoma, offering insights into personalized treatment plans. The subtypes C1, C2, and C3 differ in their genetic profiles and tumor microenvironments, guiding the use of specific therapies.
Advances in NGS have revealed non-coding regions' role in gene regulation and disease etiology. Targeting non-coding elements implicated in disease may lead to tailored therapies.
Chitinase-3-like protein 1 (CHI3L1) is recognized for its unique ability to influence multiple pathophysiological processes, despite lacking enzymatic activity. Elevated levels of CHI3L1 correlate with fibrosis severity and demonstrate superior diagnostic efficacy compared to conventional markers.
Researchers at WashU Medicine found that clonal hematopoiesis, a condition caused by mutated blood stem cells, is more common among individuals with inherited mutations that increase cancer risk. Those with inherited mutations had a higher risk of developing blood cancer if their stem cell clones acquired additional harmful mutations.
SOX2 is crucial in tumor growth, spread, and resistance to therapy, influencing cell proliferation, apoptosis resistance, and EMT. Elevated SOX2 levels are associated with poor prognosis and enable cancer cells to adapt to therapeutic pressure.
Researchers explore the potential of boosting mitochondrial biogenesis to alleviate acute kidney injury by targeting energy metabolism, stress resistance, and cell survival. Promising compounds like resveratrol and ZLN005 enhance mitochondrial function while minimizing toxicity.
The study reveals how genetic mutations in fucosyltransferases contribute to disease susceptibility, leading to inflammatory responses, barrier dysfunction, and increased cancer risk. Aberrant fucosylation is linked to conditions such as liver cirrhosis, hepatocellular carcinoma, pancreatic cancer progression, and gastric cancer.
ADAMTS2 plays a pivotal role in collagen maturation and is associated with Ehlers-Danlos syndrome, angiogenesis, lymphangiogenesis, neurodevelopment, immune regulation, and cardiovascular diseases. Its multifunctional nature positions it as a potential therapeutic target for treating genetic disorders, cancer, and cardiovascular diseases.
This review article explores the complexities of tumor angiogenesis and endothelial cell origins, highlighting the diverse sources and mechanisms of endothelial cell development in tumors. The study outlines the dysregulation and heterogeneity of tumor blood vessels, complicating the development of effective therapies.
Research reveals that gut microbiota imbalances can contribute to cardiac dysfunction, inflammation, and metabolic disturbances in heart failure. Dietary interventions, probiotics, and fecal microbiota transplantation may offer innovative approaches for managing heart failure.
Researchers are exploring targeting ferroptosis, a regulated cell death process driven by iron accumulation and lipid peroxidation, as a novel strategy to overcome the challenge of cancer stem cells. This approach has shown promise in selectively inducing cell death in CSCs while sparing normal cells.
SETD2 plays a crucial role in regulating immune cell function, influencing tumorigenesis, development, differentiation, and function of immune cells. Targeting SETD2 could modulate immune cell functions, offering novel treatments for autoimmune diseases, inflammatory conditions, and hematological malignancies.
A study published in iScience found that cells in breast tissues of women with African ancestry send cues promoting breast cancer growth. Researchers discovered that PZP cells activate epithelial cells, allowing them to invade surrounding tissue.
A new analysis suggests that preventive mastectomy is a cost-effective way to reduce the likelihood of developing breast cancer compared to breast screening and medication. Women aged 30 or above with a lifetime breast cancer risk of 35% or more may benefit from this treatment option.
The National Institute of Standards and Technology (NIST) has released detailed genetic data about a pancreatic cancer cell, fostering progress in cancer research. The data can be used to research tumors, improve diagnostic tests, and develop new cancer treatments.
This issue of Acta Pharmaceutica Sinica B features research on intestinal aging, single-cell RNA sequencing, and cancer treatment. Articles explore therapeutic strategies for reducing frailty, inhibiting colorectal tumorigenesis, and developing preclinical candidates for acute liver injury.
Researchers identify XPR1 as critical factor in promoting ovarian cancer aggressiveness through autophagy regulation and MHC-I expression. The study suggests targeting XPR1 alongside autophagy inhibition to improve immunotherapy outcomes in ovarian cancer.
A new study identifies EMP1 as a pivotal molecule driving pancreatic cancer progression and poor prognosis. EMP1 expression was shown to promote cell proliferation, migration, and invasion through the PI3K/AKT signaling pathway.
A recent study published in Genes & Diseases reveals the relationship between immune cell characteristics, blood metabolites, and urolithiasis. The research highlights how genetically predicted blood metabolites mediate the association between specific immune cell profiles and urinary stone formation.
Pyruvate alleviates ulcerative colitis symptoms by targeting cPLA2, suppressing TNFα/NFκB signaling and reducing inflammation. Pyruvate preserves intestinal mucosal barrier integrity and normalizes tight junction proteins.
Researchers have discovered that the down-regulation of YWHAB in ovarian cancer peritoneal metastasis cells promotes YAP signaling, enhancing chemotherapy resistance and maintaining stem-like characteristics. Targeting the YWHAB-YAP pathway may lead to innovative therapeutic strategies.
Researchers explored clinical implications of loss-of-function IKBKG/NEMO mutations in the NF-κB signaling pathway. The study revealed diverse clinical manifestations associated with these mutations, including skin abnormalities, dental anomalies, and infections.
A new study reveals that SETD1B plays a critical role in supporting the growth of aggressive acute myeloid leukemia (AML) cells, particularly in those with FLT3-ITD mutations. By targeting SETD1B, researchers believe it may be possible to develop more effective treatments.
A landmark study found that the tumour immune microenvironment plays a critical role in the progression of nasopharyngeal carcinoma, paving the way for precision oncology approaches. The study discovered distinct molecular differences between NPC subtypes, which influence disease progression and treatment responsiveness.
The review highlights the indispensable value of model organisms in understanding disease pathogenesis, revealing conserved genetic pathways across species. This knowledge accelerates the identification of candidate disease genes and the testing of therapeutic strategies for rare genetic disorders.
Researchers uncover the crucial role of dermal T cell immunity in regulating hair follicle regeneration and addressing immune-mediated alopecia. The intricate relationship between T cells and hair follicle regeneration is driven by key regulatory signaling pathways that dictate the activity of epithelial stem cells.
LINE-1 elements, retrotransposons actively transcribed in zygotes, facilitate chromatin architecture opening and interact with epigenetic regulators to maintain genome stability. Understanding LINE-1 regulation could lead to novel therapeutic strategies in reproductive medicine and age-related disorders.
The tumor microenvironment in osteosarcoma plays a critical role in disease progression and treatment resistance. Targeting the interplay between cancer cells, immune components, stromal elements, and extracellular matrix is crucial for developing effective treatments.
Ribosome biogenesis is crucial for liver regeneration, hepatitis C virus infection, nonalcoholic fatty liver disease, liver fibrosis, cirrhosis, and hepatocellular carcinoma. Targeted therapies targeting ribosome biogenesis may offer new treatment options for chronic liver diseases and liver cancer.
Recent findings reveal TET1's dual role in disease progression, inhibiting malignant cell growth in certain cancers while driving oncogenic pathways in others. Abnormal TET1 activity disrupts epigenetic mechanisms, contributing to neurological disorders, metabolic diseases, and autoimmune conditions.
The review highlights the significance of fusion genes across various cancers, including hematological malignancies, lung cancer, thyroid cancer, and prostate cancer. Fusion genes disrupt normal cellular processes, leading to uncontrolled proliferation and metastatic potential.
PDX models accurately mimic human tumors, offering a powerful preclinical platform for testing novel therapies. These models have demonstrated significant promise in various types of cancer research.
Researchers have discovered a novel cell-clearance pathway linked to diseases such as Chediak-Higashi Syndrome, which affects immune system function. The study used CRISPR/Cas9 gene-editing technology and live imaging to characterize this pathway and identify key genes involved.
A study found significant gaps in testing for genetic cancer risk among patients with womb cancer, with less than half eligible receiving a blood test for Lynch syndrome. This can lead to delayed diagnosis and increased cancer risk, affecting not only the individual but also their family members.
A new study explains how the gene CDK12 drives high-grade serous tubo-ovarian carcinoma, a rare and aggressive form of ovarian cancer. Researchers discovered that inactivating CDK12 triggers an immune cell response and identified a partner gene, CDK13, as a target for a degrader or inhibitor.
The Dresden research team developed an autonomous AI agent for precision medicine that can process multimodal data and have reasoning capabilities. The AI agent reached correct clinical conclusions in 91% of cases and accurately cited relevant oncology guidelines in over 75% of its responses.
The ESMO Gynaecological Cancers Congress 2025 will convene in Vienna, Austria, from June 19-21, featuring novel data on immunotherapy combinations and emerging treatment strategies for rare gynaecological cancers. The congress will also explore innovative approaches using antibody-drug conjugates.
Researchers found that childhood kidney cancers have significantly more genetic changes than previously thought, with some tumors having up to millions of changes. This discovery challenges the existing notion that childhood cancers have few genetic variants and suggests new treatment options such as immunotherapy.
Researchers identify five distinct immunotypes in tongue squamous cell carcinoma, shedding light on why current immunotherapies fail. The study's findings highlight the need for immune-based assessments to guide treatment decisions and suggest a new approach to personalized medicine.
Researchers examined baseline characteristics of adolescent and young adult (AYA) cancer survivors seen in oncology primary care clinic, finding high rates of comorbidities and cardiovascular disease. They also studied the overexpression of IRAK4 protein in acute myeloid leukemia (AML) cells, with potential implications for treatment.
A survey of stakeholders in Japan found that incorporating patient voices into assessments of genetic conditions can recalibrate people's ideas about seriousness, shifting perceptions from a tool of societal burden reduction to individual reproductive autonomy. The study emphasizes the need for including patient voices in shaping ethic...
A new study published in Blood Cancer Discovery found that certain gene mutations and the maturity of leukemia cells affect how patients respond to venetoclax and hypomethylating agents. Researchers identified a subtype of acute myeloid leukemia with worse outcomes, particularly those without the NPM1 mutation.
A study published in Nature Communications has discovered two genetic variants linked to breast cancer in black South African women, shedding light on the genetic basis of this disease in African populations. The findings have implications for developing targeted treatments and improving cancer risk prediction tools.
DiffInvex identifies evolutionary shifts in driver gene repertoires during tumorigenesis and chemotherapy, pinpointing mutational escape routes that let cancers resist treatment. The framework reveals which genes may ignite resistance to anticancer drugs, suggesting a core circuitry boosting strategy.
Pennington Biomedical welcomes Dr. Adithya Hari, MD, with expertise in nuclear oncology and translational science, strengthening cancer research and patient-centered innovation in Louisiana. He will establish a research program focused on nuclear medicine and dedicate time to direct patient care through a clinical partnership.
A predictive model combining tumor marker readings with patients' genetic profiles enhances predictions for patient survival and surgery decision-making. The new tool accurately identifies candidates who would benefit from surgery, suggesting that current tumor marker evaluations are inadequate for these genetic profiles.
The treatment demonstrated early signals of efficacy, with 65.7% of patients experiencing lasting stable disease, and was generally well-tolerated, with most adverse events being mild and manageable.
A Phase II trial found durable antitumor activity in patients with BRCA1/2 mutations treated with olaparib and pembrolizumab, with 8.3% complete response rate
Researchers identified four specific genes linked to lethal stomach cancers, enabling potential targeted treatments and less aggressive procedures for some patients. The study's findings support a more personalized approach to treatment based on each patient's tumor biology.
Researchers developed a saliva test that uses AI to identify genetic mutations in the DPYD gene, which can affect how well cancer patients respond to chemotherapy. The study found several new mutations that could lead to severe side effects from 5-fluorouracil, a widely used chemotherapy drug.
Novel biomarkers like miRNA-34a link anthracyclines to cardiotoxicity, while stem cell therapy and nanotechnology offer potential for prevention and treatment. Traditional strategies have limitations, but new approaches hold hope for improved patient outcomes.
Researchers argue that the current paradigm of cancer as a genetic disease is unproductive due to inconsistencies in sequencing data. Alternative paradigms considering non-genetic processes, such as disruptions in gene regulatory networks and tissue organization, are proposed to guide future experiments.
A new study in the Circulation Journal reveals that babies born with heart defects may be at a higher risk of developing childhood cancer. Mothers of infants with congenital heart defects also show an increased cancer risk. The study highlights the importance of maternal factors and genetic traits in understanding this connection.
Researchers found that pancreatic cancer cells gain a survival edge by carrying copies of critical cancer genes on circular pieces of DNA outside chromosomes. The discovery highlights the importance of targeting extrachromosomal DNA in treating the disease.
Genetic changes triggered by environmental factors like pollution, diet, and stress can increase cancer risk. Nearly everyone is exposed to cancer risk factors daily, highlighting the need for public awareness and policy action to reduce exposure.
Researchers found genetic changes not exclusive to tumours and skin patches, suggesting additional factors are necessary for tumour development. The study identified a pattern of mutations in the NF1 gene that may explain why nervous system tissues are commonly affected.
A recent study reveals genes that may help predict prostate cancer outcomes, including androgen receptor AR-V7 and p160 gene family. The research suggests these genes could serve as potential prognostic biomarkers for prostate cancer, highlighting the importance of androgen signaling in disease progression.
Researchers have developed a new gene therapy that targets aggressive brain cancer, glioblastoma, with a precise delivery system. The treatment uses a novel virus to deliver a targeting drug to cancer cells, achieving cure rates of up to 90% in mouse models.
A multi-institutional study led by Mayo Clinic researchers has improved the accuracy of genetic testing for BRCA2 variants, enabling precise risk assessments and personalized treatment plans. The findings will aid in identifying patients who may benefit from targeted therapies such as PARP inhibitors.
Researchers analyzed individual cells from two craniopharyngioma subtypes to identify specific cell types, their features, and interactions. The study found distinct cell types linked to tumor development and immune response in both adamantinomatous and papillary craniopharyngiomas.